Abstract:Abstract Background: The landscape of immunotherapy, employing recombinant cytokines like interleukin-2 (IL-2), confronts challenges marked by its short half-life, systemic toxicity, and constrained tumor accumulation. These hurdles are particularly evident in the context of the immunosuppressive milieu characterizing pancreatic ductal adenocarcinoma (PDAC). Chemo-immuno-therapeutic synergies, notably those provoking immunogenic cell death (ICD), have demonstrated superior efficacy. This investigation delves into Pt-NHC as a type II ICD inducer to surmount immunosuppression and amplify antitumor immunity within a highly tumor-accumulated liposomal drug delivery system. Additionally, the co-administration of the angiotensin receptor blocker, losartan, mitigates desmoplasia in PDAC, further augmenting the efficacy of immunotherapy. Methods: To address the constraints of IL-2, a lipid-coated nanogel, IL2-Pt@Nanogel, was innovated, amalgamating silk fibroin-loaded IL-2 with Pt-NHC. The nanogel aimed to enhance IL-2 pharmacokinetics and optimize tumor targeting. Concurrently, losartan was employed to alleviate desmoplasia within the tumor microenvironment. Result: The chemoimmunotherapy nanogel, when coupled with losartan, showcased therapeutic potential in murine models of desmoplastic PDAC. Pt-NHC induced ER-localized reactive oxygen species (ROS) and DAMP release, reshaping the immunosuppressive microenvironment by repolarizing M2-type macrophages to M1 and diminishing the regulatory T-cell population. Co-delivery of IL-2 and Pt-NHC in the nanogel enhanced T-cell infiltration and activation, curbing tumor progression in primary and liver metastasized PDAC models. Importantly, the addition of losartan reduced collagen accumulation within tumors, resulting in heightened infiltration of effector T cells and more pronounced suppression of tumor growth in PDAC and metastasized liver. Conclusion: This study introduces an innovative nanogel delivery system (IL2-Pt@Nanogel) for chemoimmunotherapy, effectively addressing the challenges associated with IL-2 therapy. Leveraging the enhanced permeability and retention (EPR) effect, the nanogel improves IL-2 stability and tumor delivery. Pt-NHC incorporation induces ICD, reshaping the tumor microenvironment, and in synergy with losartan, elicits robust anticancer immunity. This strategy holds promise for clinical translation as a secure and efficient treatment for immunosuppressive and desmoplastic cancers, such as PDAC, presenting a distinctive therapeutic avenue. Citation Format: Hsuan Yu Mu, Yen-Nhi Ngoc Ta, Jing Rui Max Tham, Fu-Fei Hsu, Yu-Chieh Lin, Hsi-Chien Huang, Yun-Chieh Sung, Chih-I Huang, Ching-Ling Wu, Chao-Hung Chang, Sheng Yang, Tsung-Ying Lee, Jane Wang, Dan G. Duda, Yves Boucher, Jen-Huang Huang, Wee Han Ang, Yunching Chen. Enhancing cancer treatment Via a nanostructured chemoimmunotherapy gel facilitating interleukin-2 delivery and immunogenic cell death induction [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5737.

Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Immunotherapeutic approach to reduce senescent cells and alleviate senescence‐associated secretory phenotype in mice

Strengthening the Combinational Immunotherapy from Modulating the Tumor Inflammatory Environment via Hypoxia-Responsive Nanogels

Abstract 5737: Enhancing cancer treatment Via a nanostructured chemoimmunotherapy gel facilitating interleukin-2 delivery and immunogenic cell death induction

Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy

Sequential depletion of myeloid-derived suppressor cells and tumor cells with a dual-pH-sensitive conjugated micelle system for cancer chemoimmunotherapy

Nanotechnology-mediated Immunochemotherapy Combined with Docetaxel and PD-L1 Antibody Increase Therapeutic Effects and Decrease Systemic Toxicity.

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

A Novel Bifunctional Fusion Protein Comprising of TGF-βRII trap and IL15/IL-15Rα as an Immunotherapeutic against Cancer

Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade

Depleting Tumor Infiltrating B Cells to Boost Antitumor Immunity with Tumor Immune-Microenvironment Reshaped Hybrid Nanocage

Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy.

Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy

Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1

Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy.

Serial Assessment Of Circulating T Lymphocyte Phenotype And Receptor Repertoire During Treatment Of Non-Muscle Invasive Bladder Cancer With Adoptive T Cell Immunotherapy

Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy

Ternary Regulation of Tumor Microenvironment by Heparanase‐Sensitive Micelle‐Loaded Monocytes Improves Chemo‐Immunotherapy of Metastatic Breast Cancer